ArticleJAMA oncology2017

HER2-Specific Chimeric Antigen Receptor-Modified Virus-Specific T Cells for Progressive Glioblastoma: A Phase 1 Dose-Escalation Trial.

Nabil Ahmed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.